Siglec1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| | |
|---|---|
| **Gene Symbol** | SIGLEC1 |
| **Full Name** | Sialic Acid Binding Ig-Like Lectin 1 |
| **Chromosomal Location** | 20p13 |
| **NCBI Gene ID** | [6614](https://www.ncbi.nlm.nih.gov/gene/6614) |
| **OMIM ID** | [600738](https://www.omim.org/entry/600738) |
| **Ensembl ID** | ENSG00000158850 |
| **UniProt ID** | [Q9Y248](https://www.uniprot.org/uniprot/Q9Y248) |
| **Associated Diseases** | Alzheimer's Disease, Neuroinflammation |
SIGLEC1 (also known as CD169 or Sialoadhesin) is a member of the siglec family of sialic acid-binding receptors. It is expressed primarily on macrophages and microglia and functions in:
The study of Siglec1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The SIGLEC1 Gene is involved in various cellular processes in the nervous system. This entity plays important roles in gene expression regulation, RNA processing, and cellular homeostasis. Dysfunction has been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
The SIGLEC1 Gene participates in multiple molecular pathways critical for neuronal health. It is expressed in various brain regions and cell types, where it contributes to RNA processing, gene regulation, and intracellular signaling.
Alterations in SIGLEC1 Gene expression or function have been associated with several neurodegenerative conditions. Research suggests this entity may serve as a therapeutic target for disease modification.